Merus (MRUS) identified as a top healthcare stock pick with potential for growth.

From Yahoo Finance: 2025-04-17 23:02:00

In a recent article, we listed the 10 best high short interest stocks to buy now. Merus (MRUS) is analyzed to see how it compares to other high short interest stocks. Aditya Bhave of BofA Securities discussed the impact of tariffs on inflation, stating they are generally stagflationary but could be disinflationary due to uncertainty.

Bhave referenced Fed Chair Jerome Powell’s focus on price stability and the Fed’s likely approach to maintaining current policies. The discussion also touched on the Fed’s response to tariff-induced supply chain disruptions during the COVID-19 pandemic, emphasizing the importance of timely action.

Stock screeners identified 10 highly shorted stocks popular among elite hedge funds and analysts. These stocks, ranked by hedge fund interest, present opportunities for investors to potentially outperform the market by following hedge fund activity. Hedge fund data was sourced from Insider Monkey’s database.

Merus (MRUS) is a clinical-stage immuno-oncology company with a bispecific antibody pipeline, including BIZENGRI. The FDA approved BIZENGRI for certain cancer indications based on clinical trial data, with continued approval dependent on confirmatory trials. Collaboration revenue decreased, but BIZENGRI’s approval represents a new revenue driver.

TimesSquare Capital Management noted Merus N.V. (MRUS) as a top healthcare stock pick in its Q2 2024 investor letter. The company’s pipeline of bispecific antibodies targeting solid tumors positions it well for growth. MRUS ranks 6th on the list of best high short interest stocks to buy now, with potential for growth.

For investors seeking AI stocks with high potential returns, there are opportunities beyond MRUS. A specific AI stock has shown significant gains in 2025, outperforming popular AI stocks. Those interested in AI investments should explore options that offer promising returns within a shorter timeframe.

Read more: Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now?